Article

Use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for multiplex genotyping

Bevital AS, c/o Section for Pharmacology, University of Bergen, Bergen, Norway.
Advances in clinical chemistry (Impact Factor: 4.3). 01/2011; 53:1-29. DOI: 10.1016/B978-0-12-385855-9.00001-1
Source: PubMed

ABSTRACT After completion of the human genome project, the focus of geneticists has shifted to elucidation of gene function and genetic diversity to understand the mechanisms of complex diseases or variation of patient response in drug treatment. In the past decade, many different genotyping techniques have been described for the detection of single-nucleotide polymorphisms (SNPs) and other common polymorphic variants. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) is among the most powerful and widely used genotyping technologies. The method offers great flexibility in assay design and enables highly accurate genotyping at high sample throughput. Different strategies for allele discrimination and quantification have been combined with MALDI (hybridization, ligation, cleavage, and primer extension). Approaches based on primer extension have become the most popular applications. This combination enables rapid and reliable multiplexing of SNPs and other common variants, and makes MALDI-TOF-MS well suited for large-scale studies in fine-mapping and verification of genome-wide scans. In contrast to standard genotyping, more demanding approaches have enabled genotyping of DNA pools, molecular haplotyping or the detection of free circulating DNA for prenatal or cancer diagnostics. In addition, MALDI can also be used in novel applications as DNA methylation analysis, expression profiling, and resequencing. This review gives an introduction to multiplex genotyping by MALDI-MS and will focus on the latest developments of this technology.

Download full-text

Full-text

Available from: Klaus Meyer, Aug 25, 2015
2 Followers
 · 
288 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ca0.5Zr2(PO4)3:Eu2+, Sr0.5Zr2(PO4)3:Eu2+, and Ca0.5Zr2(PO4)3:Eu2+, Sm3+ orthophosphates prepared through precipitation using sol-gel processes are analogs of NaZr2(PO4)3 (NZP) and crystallize in space group R $\bar 3$ . Their crystallographic parameters determined by X-ray diffraction are consistent with the interatomic distances extracted from EXAFS data. Their luminescence spectra obtained under excitation in the range 300–400 nm contain emission bands between 425 and 525 nm. Substitution of the larger sized cations Eu2+ and Sm3+ for Ca2+ shifts the emission bands to shorter wavelengths and reduces their width because of the decrease in the effect of the crystal field. Analysis of the spectra indicates that Eu2+ occupies two types of crystallographic sites (independent interstitial sites of different sizes and shapes in the NZP framework structure). Codoping with Eu and Sm has ensured luminescence with chromaticity coordinates approaching those of white light: (x = 0.27, y = 0.34).
    Inorganic Materials 01/2012; 49(1). DOI:10.1134/S0020168513010032 · 0.51 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A multiplex DNA microarray chip aimed at the identification of allelic polymorphisms was developed for simultaneous detection of swine disease resistance genes underlying malignant hyperthermia (RYR), postweaning diarrhea, edema disease (FUT1), neonatal diarrhea (MUC4), and influenza (MX1). The on-chip detection was performed with fragmented polymerase chain reaction (PCR)-amplified products. Particular emphasis was placed on the reduction of the number of PCR reactions required. The targets were biotin labeled during the PCR reaction, and the arrays were detected using a colorimetric methodology. Target recognition was provided by specific capture probes designed for each susceptible or resistant allelic variant. Sequencing was chosen as the gold standard to assess chip accuracy. All genotypes retrieved from the microarray (476) fit with sequencing data despite the fact that each pig was heterozygote for at least 1 target gene.
    Journal of veterinary diagnostic investigation: official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc 05/2012; 24(3):479-88. DOI:10.1177/1040638712442878 · 1.23 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dual antiplatelet therapy is the cornerstone in the management of acute coronary syndromes (ACS) and prevention of stent thrombosis (ST). Genetic polymorphisms in CYP2C19 gene involved in hepatic activation of clopidogrel leads to clopidogrel non-responsiveness and may influence clinical outcomes. These polymorphisms in CYP2C19 gene and their impact on clinical outcome in coronary artery disease (CAD) have not been studied in Indian population. We studied 110 consecutive patients (mean age 55.7 ± 10.7 years; 90% male) taking clopidogrel with angiographically proven CAD for various genetic polymorphisms in CYP2C19 gene. Relationship between loss of function mutation and clinical presentation with recurrent ACS including ST was analyzed. Out of 110 patients, 26 (23.64%) had normal genotype, 52 (47.23%) had loss of function mutation *2 and 39 (35.45%) had a gain of function mutation *17, 7 (6.36%) patients were undefined metabolizers (*2/*17) which were excluded from analyses. Final analyses included 103 patients, with 45 (40.90%) having loss of function. Overall 51 patients had ACS, with 27 developing recurrence while on clopidogrel. The prevalence of loss of function mutation was no different between the group with recurrences and those without recurrences (55.6% vs. 50%, p = 0.7). Two patients developed ST while on clopidogrel; both had loss of function mutation. CYP2C19 gene polymorphisms are common in Indian population. Loss of function mutation status did not affect the clinical outcomes. A larger study also considering P2Y12 receptor polymorphisms together with platelet activity testing, may be required to establish the role of CYP2C19 gene polymorphisms in clinical practice.
    Indian Heart Journal 01/2013; 66(1):16-24. DOI:10.1016/j.ihj.2013.10.001 · 0.17 Impact Factor
Show more